SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-21-004066
Filing Date
2021-11-10
Accepted
2021-11-10 16:03:03
Documents
62
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-20210930.htm   iXBRL 10-Q 2861227
2 EX-10.1 ovid-ex10_1.htm EX-10.1 24099
3 EX-31.1 ovid-ex31_1.htm EX-31.1 20860
4 EX-31.2 ovid-ex31_2.htm EX-31.2 20879
5 EX-32.1 ovid-ex32_1.htm EX-32.1 10683
6 GRAPHIC img41446606_0.jpg GRAPHIC 300289
  Complete submission text file 0000950170-21-004066.txt   9260988

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20210930.xsd EX-101.SCH 43872
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20210930_def.xml EX-101.DEF 177317
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20210930_lab.xml EX-101.LAB 394374
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ovid-20210930_cal.xml EX-101.CAL 39203
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20210930_pre.xml EX-101.PRE 286112
12 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20210930_htm.xml XML 1487255
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 211396454
SIC: 2834 Pharmaceutical Preparations